Duloxetine Capsule, Delayed Release
Product Images NDC 63187-612

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63187-612). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

FDA Label Image

Figure 2: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (gad Study 4) (Duloxetine Fig2)

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)
The text is a chart or a figure description showing the effectiveness of different doses of Duloxetine in relieving pain (DPNP-1) for patients. There are three doses measured (2x60mg daily, 1x60mg daily, and 1x40mg daily) and a placebo group. The chart shows the percentage of patients who reported improvement in pain at different levels, ranging from 10% to 100%. There is no additional information available.*
FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)
The text describes a graph showing the percentage of patients who achieved various levels of pain relief through a medication referred to as Duloxetine taken once daily, compared to a placebo. The graph shows percentage improvement in pain from a baseline with a focus on chronic lower back pain.*
FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)
This text is a table or a figure display and does not provide enough information to generate a useful description.*
FDA Label Image

63187-612-60 (Duloxetine Fig9)

63187-612-60 (Duloxetine Fig9)
This is a medication label for Duloxetine 30mg, a prescription drug that comes in a bottle with 30 delayed-release capsules. Each capsule contains 33.7mg of duloxetine hydrochloride equivalent to 30mg of duloxetine. The capsules are blue opaque/white opaque, filled with white/off-white pellets and imprinted with X02. The product ID is RD061230, distributed by Citron Pharma LLC, made in India. It is important to keep the medication out of reach of children and store it at room temperature. There are lot and expiry numbers provided, and the medication guide should be dispensed to each patient separately. The product was relabeled by Proficient Rx LP, located in Thousand Oaks, CA.*
FDA Label Image

Structure (Duloxetine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.